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Recently, regenerative medicine has become a highlighted ﬁeld because it has great potential to induce a
paradigm shift of supportive conventional therapy into deﬁnitive treatment. The cornea is the avascular,
transparent, dome-shaped outermost layer of the eyeball, and it consists of three layers: epithelium,
stroma, and endothelium. Conventional corneal transplantation, known as keratoplasty, has two main
problems, a donor shortage and immunological rejection. Therefore, regenerative medicine has been
applied to overcome these challenges. Regenerative medicine involving the corneal epithelium has been
clinically applied, along with an understanding of corneal epithelial stem cell biology, earlier than that of
the corneal stroma or endothelium. Thus, the effectiveness and safety of cultivated corneal or oral
mucosal epithelial cell sheet transplantation have been reported by many researchers. Clinical studies on
regenerative medicine for corneal stroma or endothelium have begun after basic and nonclinical study.
Translational research has been performed to make corneal regenerative medicine a universal therapy.
This article reviews corneal regenerative medicine.
© 2016, The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Contents
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The cornea is the avascular, transparent, dome-shaped outer-
most layer of the eyeball. The main optical function of the cornea,
together with the lens, is the refraction of light to focus on the
retina. Thus, the cornea and lens in the eye function similarly to the
lens in a camera, while the retina functions analogously to ﬁlm in a
camera (Fig. 1). The cornea consists of three layers: cornealsting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
Fig. 1. Structure of the eyeball. The structure of the eyeball is similar to that of a camera. The cornea and lens in the eyeball function similarly to the lens in a camera. The retina in
the eyeball functions similarly to ﬁlm in a camera.
Y. Oie, K. Nishida / Regenerative Therapy 5 (2016) 40e45 41epithelium, stroma, and endothelium (Fig. 2). All of the layers play
important roles to maintain corneal homeostasis. The corneal
epithelium blocks the passage of foreign materials, including bac-
teria, fungi, and dust into the eye and provides a smooth surface
that absorbs oxygen from the tear ﬁlm. The corneal stroma is the
middle connective tissue, and it consists of three main groups of
proteins, collagens, proteoglycans, glycoproteins, and a small
amount of stromal cells known as keratocytes. Regular alignment
and the consistent diameter of collagen ﬁbers are crucial for the
maintenance of transparency and the strength of the cornea. The
corneal endothelium is a single cell layer that forms a boundary
between the cornea and the anterior chamber. Proteoglycans are
associated with stromal collagens that bind to water and produce a
pressure gradient. A major function of the corneal endothelium is
to maintain corneal transparency using Na/K ATPase pumpFig. 2. Structure of the cornea and corneal disease. The cornea consists of three layers: epi
epithelial disease (e.g., limbal stem-cell deﬁciency), stromal disease (e.g., dystrophy), and efunction, which regulates corneal hydration [1]. In addition, the
endothelium forms leaky tight junctions by permitting a para-
cellular pathway of aqueous humor into the cornea.
2. Regenerative medicine for corneal epithelium
2.1. Corneal epithelium and limbal stem cells
The corneal epithelium is stratiﬁed squamous nonkeratinized
epithelium. The thickness of the corneal epithelium has been re-
ported to be 48e53 mm [2e7]. This layer is ﬁve to seven cells thick,
and consists of small basal cells, ﬂattened middle cells (wing cells),
and polygonal ﬂattened superﬁcial cells.
It has been proposed that corneal epithelial stem cells are
located in the basal layer of the limbus, the transitional zonethelium, stroma, and endothelium. Vision can deteriorate due to disease in any layer:
ndothelial disease (e.g., bullous keratopathy).
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retaining cells in the limbus [8], the higher proliferative potential
of limbal basal cells than that of other parts of the cornea [9], the
lower expression of the differentiation marker by limbal basal cells
[10], the successful reconstruction of the corneal epithelium by
limbal transplantation in patients with limbal stem-cell deﬁciency
[11], and the centripetal movement of pigmented cells in the cornea
[12]. Several markers, including p63 [13], ATP-binding cassette
subfamily G member 2 (ABCG2) [14], N-cadherin [15], NGF re-
ceptors (TrkA) [16], integrin a6 [17], and ABCB5 [18] have been
reported as candidate markers of limbal stem cells. However, a
speciﬁc marker has not yet been identiﬁed.
Clinically, the limbal characteristic observation “palisades of
Vogt” suggests normal corneal epithelial stem cell function. How-
ever, Dua HS et al. reported that the role of limbal epithelial stem
cells is limited in the physiological homeostasis of the corneal
epithelium, and corneal central basal cells are independently
capable of regenerating and maintaining the corneal epithelial
layer [19]. Recently, a new phenomenon, “limbal epithelial crypts
(LEC)”, has been reported as a putative limbal stem cell niche
[20,21]. Cells within the LEC have the phenotype of CK3-/CK19þ/
CD34-/Vimentinþ/p63þ/Connexin43þ/MlB(Ki67)-.2.2. Limbal stem-cell deﬁciency
If limbal stem cells are depleted, then corneal neo-
vascularization occurs, and stem-cell deﬁciency (LSCD). The caus-
ative diseases of LSCD are classiﬁed in Table 1 [22,23].Table 1
Causative diseases of limbal stem-cell deﬁciency.
Category Disease
Congenital Aniridia, sclerocornea





Fig. 3. Ocular surface reconstruction by autologous transplantation of tissue-engineered ce
whole epithelial cell layers was excised from the oral cavity of a patient. The cells were then s
a cell sheet by reducing the culture temperature. The cells were then transplanted onto thIn patients with LSCD, functional stem cells must be trans-
planted to sustainably reconstruct the ocular surface. Although
limbal autograft transplantation and keratolimbal autograft have
been performed, long-term outcomes have been reported to be
unsatisfactory due to bacterial keratitis or immunological rejection
[11,24,25]. Patients with LSCD often have coexisting ocular abnor-
malities, including severe dry eye due to the destruction of lach-
rymal glands, trichiasis, eyelid defect, and chronic inﬂammation.
Furthermore, these abnormalities will negatively affect stem cell
survival after transplantation. Thus, the management of these
ocular surface abnormalities and stem cell transplantation is very
important for the treatment of LSCD.
2.3. Cultivated epithelial cell sheet transplantation
Pellegrini G et al. reported that the ocular surface in patients with
LSCD caused by ocular burns can be restored using expanded limbal
stem cells for as long as two years [26]. Following this report, many
researchers have reported the effectiveness and safetyof thismethod
for ocular surface reconstruction. The same group reported that
permanent restoration of a transparent corneal epithelium was
attained in76.6%of eyesusing autologous limbal stemcells cultivated
on ﬁbrin in patients with ocular burns [27]. The EuropeanMedicines
Agency has recommendedHoloclar, cultivated limbal epithelial stem
cells, for approval in the European Union in 2014. Holoclar is the ﬁrst
regenerative and cellular therapeutic product in the cornea ﬁeld
worldwide. It is believed that this technique should be more widely
used as a universal treatment because its effectiveness and safety
have been conﬁrmed by many clinical studies and trials.
Although this treatment has been successfully applied for pa-
tients with LSCD, it can only be used for unilateral patients because
limbal tissue from the healthy eye is used as the cell source. Thus,
the patients' own oral mucosal epithelial cells are used as a cell
source for bilateral patients, and cultivated oral mucosal epithelial
cell sheet transplantation (COMET) has been reported (Fig. 3) [28].
Although corneal neovascularization or subepithelial scarring can
occur following COMET, long-term outcomes are favorable (Fig. 4)
[29,30].ll sheets fabricated from oral mucosal epithelial cells. Oral mucosal tissue containing
eeded onto a temperature-responsive culture dish. The cultured cells were harvested as
e corneal surface of the patient.
Fig. 4. Slit lamp photographs of patients before and after cultivated oral mucosal epithelial cell transplantation. (A) The left eye has a total limbal stem-cell deﬁciency. The visual
acuity (VA) was 20/2000. (B) One year postoperatively, the corneal epithelial clarity was well maintained, and the VA was 20/33.
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somatic cells by introducing factors, Oct3/4, Sox2, c-Myc, and Klf4,
under embryonic stem (ES) cell culture conditions [31,32,33].
Induced pluripotent stem (iPS) cells can be applied to regenerative
medicine, drug development, and analysis of disease pathogenesis.
Co-ordinate ocular development from human iPS cells and the re-
covery of corneal function have recently been reported [34]. The
ﬁrst-in human clinical trial of anterior eye transplantation to
restore visual function using this method will be performed in the
near future.
3. Regenerative medicine for the corneal stroma
3.1. Structure of the corneal stroma
The corneal stroma consists of collagens and associated pro-
teoglycans, other glycoproteins, and corneal stromal cells (kerato-
cytes). In total, 71% of the dry weight of the cornea is collagen [35].
Collagen and proteoglycans form the scaffolding of many tissues,
including the cornea, cartilage, skin, and tendon. These two types of
proteins make up the majority of the extracellular matrix between
cells. The cellular component (keratocytes) is thought to represent
only 2e3% of the matrix [36].
Collagens can be divided into several subfamilies based on their
structure and organization [37]. Fibrillar collagens, including types I
to III, V, and XI, have the same general structure and play an
important role in the formation of cross-banded ﬁbrils. Other types
of collagens can be categorized as nonﬁbrillar collagens. For
example, basement membrane (type IV) collagen forms networks.
Type VI collagen forms beaded ﬁlaments. Type VII collagen forms
anchoring ﬁbrils and is involved in anchorage of the basement
membrane. Corneal collagens mostly consist of type I with smaller
amounts of types III, V, and VI [38,39]. Both the mean diameter of
collagen ﬁbers and the mean distance between these ﬁbers are
homogeneous and 400e700 mm. These anatomical characteristics
are thought to be crucial for the maintenance of corneal trans-
parency because the incident ray of light by each collagen ﬁber is
canceled by interference from other scattered rays, which allows
light to pass through the cornea.
The second major group of proteins in the corneal stroma is
proteoglycans. They consist of a core protein containing one or
more glycosaminoglycan (GAG) side chains, which are also
known as mucopolysaccharides. Approximately 65% of the
corneal GAG is keratin sulfate, and the remaining amount is
chondroitin sulfate and dermatan sulfate. The core proteins of the
corneal stroma include lumican, keratocan, and mimecan as
keratin sulfate proteoglycans, as well as decorin and biglycan aschondroitin sulfate or dermatan sulfate. GAG has the ability to
absorb and retain large amounts of water, and it generates stro-
mal swelling pressure. The precise regulation of the diameter and
orientation of ﬁbers, as well as the interﬁbrillar spaces, is partially
attributed to the interactions between glycosaminoglycans and
collagens [37].
Keratocytes predominantly comprise cells of the corneal stroma.
It is believed that they turn over approximately every 2e3 years.
They are connected with extended long processes by gap junctions.
Keratocytes are normally quiescent but can change into myoﬁbro-
blasts, which are positive for a-smooth muscle actin in response to
various types of insults to the stroma [40].
3.2. Treatment for corneal stromal disease
Penetrating keratoplasty has been the only choice for corneal
stromal disease for more than half a century, but the adoption by
specialist surgeons of newer forms of lamellar transplantation
surgery, which selectively replaces only diseased layers of the
cornea, has been a fundamental change in recent years [41]. Deep
anterior lamellar keratoplasty, one procedure of anterior lamellar
transplantation, has an advantage over penetrating graft in elimi-
nating the risk of endothelial rejection. Once endothelial rejection
occurs, it can directly cause graft failure due to endothelial
dysfunction. However, donor shortage is a very large problem in
many countries that perform keratoplasty.
3.3. Regenerative medicine for corneal stromal disease
Many researchers have reported basic or clinical studies of
regenerative medicine for corneal stromal diseases. Grifﬁth M et al.
reported functional human corneal equivalents constructed from
cell lines [42] and have also applied corneal implants made from
interpenetrating networks of cross-linked recombinant human
collagen type III and 2-methacryloyloxyethil phosphorylcholine in
three patients [43]. The potential use of human limbal biopsy-
derived stromal, dental pulp stem cells, and embryonic stem cell-
derived keratocytes for corneal disorders has been reported
[44,45,46]. These types of cells can differentiate into keratocytes
that are positive for keratocan [47]. In addition, mesenchymal stem
cells have a great capacity for differentiation and immunosup-
pression. It has been reported that they have an ability to differ-
entiate into corneal epithelial cells, keratocytes, and endothelial
cells [48]. There have been several clinical trials using mesen-
chymal stem cells in patients with corneal disease, such as sterile
corneal epithelial defect and chronic graft-versus-host disease
[49,50].
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Corneal endothelial dysfunction causes bullous keratopathy,
which is clinically characterized by corneal epithelial and endo-
thelial edema, Descemet's membrane fold. Cataract surgery and
Fuchs' endothelial corneal dystrophy are is a main causes of bullous
keratopathy. In Japan, bullous keratopathy secondary to laser iri-
dotomy is the second most common cause [51]. Although pene-
trating keratoplasty has been the only treatment for bullous
keratopathy, endothelial keratoplasty for a long time, endothelial
keratoplasty including Descemet-stripping automated endothelial
keratoplasty or Descemet membrane endothelial keratoplasty, has
recently been applied in an increasing number of patients [52e56].
Cultivated corneal endothelial transplantation using the ROCK in-
hibitor has also been reported [57e62]. This novel treatment has a
great possibility of overcoming the large problem of donor
shortage. Another potential solution is corneal endothelium
derived from corneal stroma stem cells [63,64]. It was reported that
the corneal endothelium was induced by retinoic acid and Wnt/b-
catenin signaling. Autologous or allogenic therapy using this tech-
nology can be applied in the near future.5. Translational research towards a universal therapy
Universal therapy means that patients can access treatment
regardless of their location. To achieve this goal, translational
research must be performed to develop new treatment methods
based on basic research ﬁndings in the health care ﬁeld (Fig. 5).
Translational research steps include basic research, nonclinical
research, clinical research, and universal therapy. However, there is
a gap between basic research and clinical research known as “Devil
River”. For example, even if a novel induction method of pluripo-
tent ormultipotent stem cells to a speciﬁc type of cell is established,
the safety of animal-derived materials used during the induction
process must be conﬁrmed prior to the ﬁrst clinical application. A
patent that sufﬁciently covers the developed method must be also
acquired. An interval between clinical research and clinical trials
can be called the “Valley of death.” Here, regulatory issues must be
addressed before the clinical trial, and the cost for the clinical trial
and the approval process must be covered. A gap between clinical
trials and universal therapy can be called a “Darwinian sea,” which
indicates severe natural selection in the market. In the ﬁeld of
regenerative medicine, the cost of maintaining and running the
good manufacturing practice facility where the cells areFig. 5. Translational research. The steps from basic research to universal therapy are
referred to as “translational research”.manipulated is high. In the market, the cost-beneﬁt performance
should be evaluated. Thus, manufacturing cost should be cut in
some way (see Fig. 5).
Multidisciplinary groups, including not only basic scientists and
clinicians but also bioinformaticists, statisticians, engineers and
industry experts, are required for translational research. Scientists
will be evaluated using business techniques, such asmilestones and
the ability to work in multidisciplinary groups, rather than by their
publications alone [65].
Our group has been working on translational research using
cultivated oral mucosal epithelial cell sheets [66]. We developed a
new culture method without xenogenic feeder layer nor bovine
fetal serum, sheet transportation technique [67,68]. We are per-
forming amulticenter clinical study and trial based on these results.
Unfortunately, COMET has been performed in a limited number of
institutes for a small number of patients thus far. Approval as a
regenerative and cellular therapeutic product is essential for uni-
versal treatment. One goal of our translational research is that
many patients access this treatment and beneﬁt from the approved
products as a universal therapy.
The Regenerative Medicine Promotion Law and the Act on the
Safety of Regenerative Medicine was recently established in Japan.
The Pharmaceutical Affairs Lawwas revised as the Pharmaceuticals,
Medical Devices and Other Therapeutic Products Act (PMD Act),
which introduced early approval for regenerative and cellular
therapeutic products. Before this revision, conﬁrmation of a prod-
uct's effectiveness and safety was required for its approval. How-
ever, the conﬁrmation of safety and the suggestion of effectiveness
are now required for conditional approval. These changes will
expedite the approval of regenerative medicine products and will
promote the standardization of regenerative medicine.
There are two ways for a new treatment to become widely
available as a general medical treatment: coverage by health in-
surance or approval as a medical device under the PMD Act. A
treatment that receives approval as a regenerative and cellular
therapeutic product under the PMD Act will be more accessible to
patients because all hospitals can purchase commercially available
products. We believe that it is time to make regenerative medicine
a universal therapy.Conﬂicts of interest and source of funding
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